FarmavitaR+

1. Clinical Trial in India
(Clinical Trilas/Asia)

... cancer, diabetes and testotoxicosis and are conducted on adults and, in certain cases, children. Likewise, Johnson & Johnson and Eli Lilly are conducting respectively eight studies in India, while seven ...

2. Russia’s Emerging OTC Market Holds Problems As Well As Promise
(Regulatory Affairs/Europe not-EU)

... regulations and lengthy registration timelines may hinder entry. "Russia is one of the biggest pearls," said Amra Pasovic, new and emerging markets regulatory affairs director with Johnson & Johnson ...

3. Johnson & Johnson
(Reports/Company Report)

Johnson & Johnson: PharmaVitae Profile This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio ...

4. Biogenerics
(Biosimilars/Biosmimilars)

... of low red blood cell counts. Pliva said its EPO is a generic version of Johnson & Johnson subsidiary Janssen Cilag’s Eprex (epoetin alfa). The approval, in its home market of Croatia, ...